Earlier, we developed a new format of a chimeric antigen receptor, called TCR fusion construct (TRuC). In the TRuC the single chain variable fragment recognizing the tumor antigen is directly fused to the TCR. We had only tested the TRuC in the frame of an alpha beta TCR. Here, we expressed an anti-CD19 TRuC in primary, human gamma delta T cells. We show that the resulting TRuC gamma delta T cells were re-programmed to better kill hematopoietic and solid tumor lines. Our data further suggest that the Vdelta2 T cells were better killers than the Vdelta1 T cells. Thus, gamma delta TRuC T cells might be a new approach for cancer immunotherapy.